MBIO DIAGNOSTICS INC

MBIO DIAGNOSTICS INC specializes in advanced diagnostic system development and molecular assay design, leveraging cutting-edge biosensing and point-of-care technologies to support public health and biomedical research initiatives. Their core capabilities include the engineering of rapid diagnostic platforms, nucleic acid amplification systems, and integrated lab-on-a-chip solutions, with technical expertise in assay validation, microfluidics, and analytical instrumentation for infectious disease and biomarker detection. The company differentiates itself through its focus on ruggedized, field-deployable diagnostic tools designed for low-resource environments and high-throughput screening scenarios, emphasizing reliability, speed, and regulatory readiness in complex biological sample analysis. No award history is available to infer specific agency engagements or project types, and therefore no consistent patterns of work with federal entities can be confirmed. Similarly, without contract data, it is not possible to identify primary funding agencies or the nature of any government partnerships. The company’s primary NAICS code, 541715, corresponds to research and development in the physical, engineering, and life sciences, indicating a focus on applied scientific innovation rather than commercial product sales. In practice, this suggests deep involvement in early-stage diagnostic technology development, including prototype validation, analytical method optimization, and preclinical testing frameworks aligned with FDA and CDC standards. MBIO DIAGNOSTICS INC is structured as a small business (2L) and is headquartered in Boulder, Colorado. The company holds no government certifications, and its market positioning is grounded in scientific R&D rather than large-scale procurement or systems integration. Its geographic presence is centralized in Colorado, with operations likely oriented toward academic, federal, and biotech collaborations in the life sciences corridor of the Rocky Mountain region.